Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Mass Balance of WX-081 in Healthy Chinese Volunteers
NCT06701110Phase 1Recruiting
- Sponsor
- Shanghai Jiatan Pharmatech
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sudapyridine in pulmonary tuberculosis (TB), sponsored by Shanghai Jiatan Pharmatech. Primary endpoints: Cumulative Excretion Rate of Total Radioactivity in Urine and Cumulative Excretion Rate of Total Radioactivity in Feces. Started Sep 2024; status: recruiting.
02
Drugs
sudapyridine
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT06701110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06701110.